Results 151 to 160 of about 648,282 (342)

A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. [PDF]

Clin Transl Sci, 2023
Moein A, Langenhorst J, Plan EL, Jin JY, Kågedal M, Kassir N.   +5 more
europepmc   +1 more source

Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas

Annals of Neurology, EarlyView.
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek, David F. Hanff, Pim J. French, Sarah A. van Dijk, Erik A.C. Wiemer, Olivier C. Manintveld, Martin J. van den Bent, Walter Taal   +7 more
wiley   +1 more source

Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence. [PDF]

Schizophr Bull, 2022
Czobor P, Kakuszi B, Bitter I.
europepmc   +1 more source

Predictors of post-operative response to treatment: a double blind placebo controlled study in chronic rhinosinusitis patients

, 2011
Fenna A. Ebbens, Sanna Toppila‐Salmi, E. J. J. De Groot, Jutta Renkonen, Risto Renkonen, Cornelis M. van Drunen, M.G.W. Dijkgraaf, Wytske J. Fokkens   +7 more
openalex   +2 more sources

Back Again to the Future: A New Era for Cerebroprotection

Annals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. [PDF]

Transl Psychiatry, 2023
Gomeni R, Hopkins S, Bressolle-Gomeni F, Fava M.   +3 more
europepmc   +1 more source

Heterogeneity of clinical response during placebo treatment

, 1991
Frederic M. Quitkin, Judith G. Rabkin, J W Stewart, Patrick J. McGrath, Wilma Harrison, Donald C. Ross, E Tricamo, Joseph L. Fleiss, J Markowitz, D F Klein   +9 more
openalex   +1 more source

Dose response, efficacy and safety of the endothelina receptor antagonist LU 135252 compared with placebo in patients with moderate hypertension. The HEAT study: ?ypertension, ?ndothelin ?ntagonist ?reatment [PDF]

, 2001
Radislav Nakov
openalex   +1 more source

Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic Study

Annals of Neurology, EarlyView.
Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai, Joanne Wuu, Magdalena Koziczak‐Holbro, Andrea Malaspina, Volkan Granit, Jessica P. Hernandez, Anne Cooley, Ruchika Sachdev, Lili Yu, Michael Bidinosti, Ludivine Flotte, Mark Nash, Lori L. Jennings, James D. Berry, Lucie I. Bruijn, Sophie Brachat, Michael Benatar   +16 more
wiley   +1 more source

Placebo response in pharmacological trials in patients with functional dyspepsia-A systematic review and meta-analysis. [PDF]

Neurogastroenterol Motil, 2023
Bosman M, Smeets F, Elsenbruch S, Tack J, Simrén M, Talley N, Winkens B, Masclee A, Keszthelyi D.   +8 more
europepmc   +1 more source